# Study of NM8074 in Adult C3 Glomerulopathy Patients

> **NCT05647811** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **NovelMed Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- C3 Glomerulopathy

## Interventions

- **DRUG:** NM8074

## Key facts

- **NCT ID:** NCT05647811
- **Lead sponsor:** NovelMed Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-05
- **Primary completion:** 2029-08
- **Final completion:** 2030-07
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05647811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05647811, "Study of NM8074 in Adult C3 Glomerulopathy Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05647811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*